Shattuck Labs Announces Participation in Upcoming 21st Annual Needham Virtual Healthcare Conference
April 05 2022 - 4:00PM
Shattuck Labs, Inc. (NASDAQ: STTK), a clinical-stage biotechnology
company pioneering the development of bi-functional fusion proteins
as a new class of biologic medicine for the treatment of patients
with cancer and autoimmune disease, today announced that company
management will participate in the 21st Annual Needham Virtual
Healthcare Conference being held April 11-14, 2022.
Presentation Details
Conference: 21st Annual Needham Virtual Healthcare Conference
Format: Fireside chat with covering analyst Gil Blum,
Ph.D.Presenters: Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief
Executive Officer and Andrew Neill, M.B.A., Shattuck’s Chief
Financial OfficerDate: April 11, 2022Time: 1:30 p.m. ET
A live webcast of the presentation will be available on the
Events & Presentations section of the Company’s website. A
replay of the webcasts will be archived for up to 90 days following
the presentation date.
About Shattuck Labs, Inc.Shattuck Labs, Inc.
(NASDAQ: STTK) is a clinical-stage biotechnology company pioneering
the development of bi-functional fusion proteins as a new class of
biologic medicine for the treatment of patients with cancer and
autoimmune disease, with multiple ongoing Phase 1 clinical trials.
Compounds derived from Shattuck’s proprietary Agonist Redirected
Checkpoint, ARC®, platform simultaneously inhibit checkpoint
molecules and activate costimulatory molecules within a single
therapeutic. The company’s SL-172154 (SIRPα-Fc-CD40L) program,
which is designed to block the CD47 immune checkpoint and
simultaneously agonize the CD40 pathway, is being evaluated in two
Phase 1 trials. A second product candidate, SL-279252
(PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in solid
tumors or lymphomas. Additionally, the company is advancing a
proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is
designed to bridge gamma delta T cells to tumor antigens for the
treatment of patients with cancer. Shattuck has offices in both
Austin, Texas and Durham, North Carolina. For more information,
please visit: www.shattucklabs.com.
Investor Contact: Conor RichardsonSenior
Director, Finance & Investor RelationsShattuck Labs,
Inc.InvestorRelations@shattucklabs.com
Media Contact:Stephanie Ascher Managing
DirectorStern Investor Relations,
Inc.Stephanie.ascher@sternir.com
Shattuck Labs (NASDAQ:STTK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Shattuck Labs (NASDAQ:STTK)
Historical Stock Chart
From Jul 2023 to Jul 2024